the patient remai ne d on the phenytoi n and phenobar bital. No spo ntaneo us, position al, or neck-torsion nystagmu s was obse rve d. Th e alterna te bin aur al bith erm al (A BB) test yie lded ge nera lly hypoactive res ponses in both ears ; these responses migh t have been influence d by the dru gs. The A BB tes t elicited a reduce d vest ibular res po nse left and a directional prep ond erance (DP) left. The simultaneo us binaural bith erm al tes t elicited a type 4 response, with a left-beating wa rm respon se co nsis ten t w ith the DP.
II MEDICINE CLINIC
Clinical managementofa patient with a 12-year history of a balance disorder Kenneth H. Bro okler, MD , FRC SC ; Mohamed A. Hamid, MD, PhD the patient remai ne d on the phenytoi n and phenobar bital. No spo ntaneo us, position al, or neck-torsion nystagmu s was obse rve d. Th e alterna te bin aur al bith erm al (A BB) test yie lded ge nera lly hypoactive res ponses in both ears ; these responses migh t have been influence d by the dru gs. The A BB tes t elicited a reduce d vest ibular res po nse left and a directional prep ond erance (DP) left. The simultaneo us binaural bith erm al tes t elicited a type 4 response, with a left-beating wa rm respon se co nsis ten t w ith the DP.
Asinuso ida l vertical-ax is rotatio n test sho we d a low ga in at 0.1 6 Hz and a ph ase lag at 0. 16 Hz. The re was abn orm al symmetry to the righ t at 0.08 and 0.32 Hz. Oc ular fixation suppressio n of 0.08 -Hz rotation-induced nystagmus was excellent. In all, the rotatio n test showed an inco mplete centra l vestibular compensation of a periph eral ves tibular disorder.
Findings on audio log ic tes ting did not contr ibute to the eva luatio n, but sma ll-pixel ultra th in-s lice computed 12-year history ofbalance difficulties. He had been adm itte d to a hospit al 12 years earlier for treatm ent ofnausea, vomiting, and left-upp er-qu adr ant pain , and he was given intraveno us flu ids and antibiotics. Trea tment alleviated his symptoms , but he noticed that once he was out ofbed , he
was unabl e to main tain his ba lance and had to hold on to the IV pole. Eve r since then , his symptom s had persisted. At the office, the patien t rep ort ed that he had no balan ce difficult y while lying down or sitt ing-only when sta nd ing or wa lking. He sai d the intensity of symptom s fluctuated and that period s of more severe imba lance were becom ing more freque nt. He was unable to wa lk stea dily while looking at the hor izon ; he had less difficult y whe n he looked down as he wa lked. He repo rted a possible decline in his hearing, but he experienced no tinnitu s or aura l fullness. His medical history also incl uded epilepsy, for whic h he was takin g pheny toin and ph enob ar bital, and prostate cance r. His fa mi ly history was not co ntr ibutory. A review of the hospital chart from 12 years earlier revealed that he had not received an ototoxic anti bio tic.
A clinical neurotolog ic examination revealed that the patient' s pup ils were irregul arly size d and did not respond to light. He sa id he had been aware of these abnor ma lities for many years. He performed the regular Romb erg tes t wit h some di fficult y, and he was unabl e to perform the sharpened Ro mberg test with either foot forward . Moreover, wh en he was sta nding, both of his knees we re in flex ion an d he tilted to one side. Whe n he wa lked, he exhibi ted an exaggerated sway from side to side , and it appeared that he wo uld have fa llen if a wa ll or piece of furn iture had not been pres ent to prevent a fall.
Electronystag mography (ENG) was performed wh ile DESCRIPTION CIPRDDEX' (ciprofloxacin 0.3% anddexamethasone 0.1%) Sterile Otic Suspension contains the synthetic broad-spectrum antibacte rial agent, ciprofloxacin hydrochloride, combi ned with the ant i . i n fl a m ma toc orticoste roid, dexamethasone, in a sterile, preserved suspension forotic use . Each mL of CIPRODEX Otic contains ciprofloxacin hydrochloride (equi valent to 3 mg ciprofloxacin base), 1 mg dexamethasone, and0.1mg benzalkonium chlorideas a preservative. The inactiveingredients are boric acid,sodi umchloride, hydroxyethyl cellulose, tyloxapol , acetic acid,sodium acetate, edetate disodium, andpurif iedwater. Sodium hydroxide or hydrochloric acid may be addedfor adjustment of pH. Cipr ofloxacin, a lIuoroquinolone is available as the monohydrochloride monohydrate salt of r-evelo-propyl·6·fluoro-l ,4·dihydro+ oxo-7-(I-piperazinyll-3·qui nolinecarboxylic acid. The empirical formul a is C17HI8FN303·HCI ·H20. Oexamethasone, 9·fluoro-l l lbeta),17,21·trihydroxy·16(alphal·methyl pregna·1, 4·diene-3,20·dione, is an anti-inflammatory corticosteroid. The empirical formul a is C22H29F05. CLINICALPHARMACOLOGY Pharmacokinetics: Following a single bilateral4·dropItotal dose = 0.28 mL, 0.84 mgciprolloxaci n, 0.28 mg dexamethasone) topical otic dose of CIPRODEXs Otic to pediatric patients after tympanostomy tubeinsertion, measurable plasma concentrations of ciprofloxacin and dexamethasone were observed at 6 hours following administrationin 2 of 9 patients and5 of9 patients, respectively. Mean ± SO peak plasma concentrations of ciprofloxacin were 1.39 ± 0.880 ng/mL (n=9). Peak plasma concentrations ranged from 0.543 ng/mL to 3.45 ng/mL and were on average approximately 0.1% of peak plasma concentrations achieved with an oral dose of 250·mg "'. Peak plasma concentrations of ciproll oxaci n were observed within 15minutes to 2 hours postdoseapplication. Mean ± SOpeak plasma concentrationsof dexamethasone were 1.14 ± 1.54ng/mL(n=9). Peak plasmaconcentrations ranged from 0.1 35 ng/mLto 5.10 ng/mL and were on average approximately 14% of peak concentrations reported in theliterature following anoral O.S·mgtabletdose'". Peak plasma concentrations ofdexamethasone were observedwithin 15mi nutes to 2hourspostdose application. Dexamethasone has beenaddedto aidin the resolution of the inflammatory respon se accompanying bacteri al inf ection [such asotorrhea inpediatric patients with AOM withtympanostomy tubes). Microbiology: Ciprofloxacinhas in vitroactivity agai nst a wide rang e ofgram-positive and gram-negati ve microorganisms. The bactericidal action of ciprofloxa cin results frominterference with the enzym e, aNA gyrase, which is neededfor thesynthesisof bacterial DNA. Cross-resistance has beenobserved between ciprofloxacin and other fluoroquinolones . There is generally no cross-resistancebetween ciprofloxacin and other classes ofanti bacterial agentssuch asbeta-Iactamsoraminoglycosides. Ciprofloxacin has been shown to be active against mostisolates of the following microorganisms,both in vitro and clinically in otic infections asdescribed inthe INDI CATIONS ANDUSAGE section. PRECAUTI ON S General: Aswith otherant ibacterial preparations, use ofthis product mayresul t in overgrowth of nonsusceptible organisms,including yeast andfungi . If theinfectionis notimproved afteroneweekoftreatment, culturesshould beobtainedto guidefurthertreatment If otorrhea persists after a full course oftherapy, or iftwoormoreepisodes ofotorrheaoccur withinsi xmonths, furthe r evaluation isrecommendedtoexclude an underlying condition such as cholesteatoma, foreign body, or a tumor. The systemic administration of quinalones, includi ng ciproll oxaci n at doses much higher than given or absorbed by the otic route, has ledto lesi ons or erosions of the carti lage in weight-bearingjoints and other signs of arth ropathy in immature animalsof various species. Guinea pigs dosed in the middle ear with CIPROOEJ<O Ot ic for one monthexhibited nodrug-relatedstructural or functional changes of the cochlearhair cellsand nolesions in the ossicles. CIPRODEX' Oti c was also shown to lack dermal sensitizing potent ial in the guinea p iw hen testedaccordin gto the met hodof Buehl er. Nosignsof localirritationwere found whenCIPRODEX Ot ic was applied topically in the rabbiteye. InformationforPatient s: Forotic useonly. (This produ ct is not approve d for usein the eye.) Warm the bottl e in your hand for one to two minut es priorto use andshake well immediatelybefore using. Avoid contaminating the tip with material from the ear,fing ers, or oth er sources. Protect from light If rashor allergic reactionoccurs, di scontinue use imm edi ately and contact your physician. It is very importantto usethe eardrops for as long as the doctor has instructed,even if thesymptoms improve. Discard unusedportionafter therapy is completed. Acute OtitisMedia in pedi atric patients with tympanostomytubes: Prior to administration of CIPROOEX ' Otic in patients 16 monthsand older) with acute otitismedia through tympanostomytubes , the solution should be warmed by holding the bonlein the hand for oneor two minutesto avoid dizziness which mayresultfromthe insti llation of a cold solution. Thepatientshould lie with the affect ed earupward, andthenthe drops should be instilled. The tragusshould thenbe pumped 5 times by pushing inward to facilitate penetration of the drops into the middleear . This positionshould be maintained for 60 seconds. Hepeat, if necessary, for the opposite ear Isee DOSAG E AND ADMINI STRATIONI. Acute Otitis Externa: Pri or to administrat ion of CIPRODEX' Ot ic in patients with acute otitis externa, the solution should be warmed by holding the bottle in the hand for oneor twomi nutes to avoid dizziness which mayresult from the instillat ion of a cold solution. The patient should lie with the affected ear upward, and then the drops should be instilled. Thi s position should be maintained for 60 seconds to facilitate penetration of the drops into the ear canal. Repeat, if necessary , for the opposite ear (seeDOSAGE ANDADMINISTRATIONI. Drug Interactions: Specific drug interaction studies have not been condu cted with CIPRODEX' Oti c. Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term carcinogenicity studie s in mice and rats have been compl eted for ciprolloxacin. After daily oral doses of 750 mg/kg (mice) and 250 mg/kg [rats) were admi nistered for up to 2 years, there was no evidence that ciprofl oxacin had any carcinogenic or tumorigeni c effects in these species. No long term studies of CIPROOEJ<O Otic have been periormed to evaluate carcinogenic potential. Eight in vitro mutagenicity tests have been conducted with ciprofloxacin, andthe test resul ts are listed below: Salmonella/Microsome Test (Negative).
E. coli DNA Repair Assay (Negative). Mouse Lymphoma Cell Forward Mutati on Assay (Positive).

Chinese Hamster V79 Cell HGPRT Test INegati vel, Syrian Hamster Embryo Cell Transformation Assay INegati ve), Saccharomyces cerevisiae Point Mutation Assay (Negat ive), Saccharomyces cerevisiae
Mitotic Crossover andGene Conversion Assay (NegativeI, Rat Hepatocyte DNA Repair Assay (Pos itivel . Thus, 2ofthe8testswerepositive, butresults ofthefollowing3in vivotest systems gavenegativeresults: RatHepatocyte DNA Repair Assay, Micronucleus Test1Mice).Dominant Lethal Test (Mice). Fertility studies performed in ratsat oral dosesof ciprofloxa cin upto 100 mg/kg/day revealed no evidence of impairment This would beover100 times the maximum recommended clinical dose of ototopicalciprof loxacin based upon bodysurface area, assuming total absorption of ciprofloxa cin fromthe earof a patient treatedwith CIPROOEX' Otic twiceper day accordingto labeldirect ions. Long termstudieshavenot been performedto evalu atethecarcinogenic potential of topical otic dexamethasone. Dexamethasone hasbeentestedfor in vitroandinvivo genotoxic potential andshown tobepositive inthe followingassays: chromosomal aberrations, sister-chromatid exchange inhuman lymphocytes and micronu clei and sister-chromat id exchange s in mouse bone marrow. However, the Ames/Salmonella assay, both with andwithout S9mix, didnot show anyincreaseinHi srevertants.The effectofdexamethasone onfertility hasnotbeeninvestigatedfollowing topicalotic application. However, the lowest toxic dose of dexamethasone identified followingtopical dermal application was 1. 802mglkgin a 26·week studyin male rats and resultedin changes to the testes, epididymis,spermduct, prostate,semi nal vessicle,Cowper' s glandand accessoryglands.The relevance of this study forshorttermtopical otic use isunknown. Pregnancy Teratog enic Effects. Pregnancy CategoryC: Reproduction studieshave been periormed in rats and mice using oral doses of up to 100mg/kg and IV dosesupto 30 mg/kg andhaverevealed no evidence of harm to the fetusas a result of ciprolloxacin. In rabbits, ciprolloxacin (30 and100 mg/kg orallyl produced gastrointestinal disturbancesresulting in mat ernal weight loss andan increased incidence of abortion, but noteratogenicity wasobservedat either dose. After intravenous administration ofdoses up to 20 mg/kg, nomaternal toxicity wasproduced in therabbit, and noembryotoxicityor teratogenicitywasobserved. Cortic osteroids aregenerally teratoge nic in laboratoryanimals when administered syste mically at relatively low dosage levels. The more potent corticosteroids have beenshownto be teratogenic afterdermal application in laboratoryanimals. Animal reproduction studieshave not been conducted with CIPROOEX ' Otic. Noadequateandwell controlledstudieshavebeen performedin pregnant women. Cautionshould be exercised when CIPROOEX ' Otic is usedby a pregnant woman. NursingMothers:Ci profloxacinandcorticosteroids, asa class, appearinmilkfollowing oraladmi nistration. Dexamethasone in breast milk could suppressgrowth, interfere with endogenous corticosteroid production,or caus e other untoward effects. It is notknown whether topical otic admi nistration ofciprofloxacin or dexameth ason e could result in sufficient systemic absorption to produ ce detectable quantities in human milk. Becauseof the potential forunwant edeffects innur sing inf ants, a decisionshoul d be made whether to disc ontinuenursing or to discontinuethedrug, taking int o account the importance ofthedrug to the mother. Pediatric Use: The safety and efficacy of CIPRODEX ' Otic have been establishe d in pediat ric patient s 6monthsand older(937patients)in adequate andwell-controlled clinicaltrials. Although no dataare available onpatients lessthan age 6 months, there arenoknown safetycon cernsordifferencesinthedi sease processinthispopulationthatwould preclude useofthis product (SeeDOSAGE ANDADMINISTRATION.) Noclinicallyrelevant changes in hearingfunctionwereobserved in 69pediatric patients(age4to 12yearsl treatedwith CI PRO OEX ' Otic andtested for audiometric parameters.
ADVE RSE REACTIONS
In Phases II andIII clinical trials, a total of 937 patients were treated with CIPRODEX' Ot ic. This included 400 patients with acuteotitis medi a with tympanostomy tubesand537 patients with acuteotitis externa. The reported treatment·related adverse eventsare listedbelow: Acute Otitis Media in pediatric patients with tympanostomy tubes: The following treatment·related adverse eventsoccurredin0.5% ormore of the patient swithnon-intacttympanic membranes.
Adverse Event
Incidence fN=400) Ear discomf ort 3.0% Ear pain 2.3%
Ear precipitat e treslduel 0.5% Irritabili ty 0.5% Taste perversion 0.5% Thefollowingtreatment·relatedadverseevents wereeach report edIna Singl e pati ent tympanostomytube blockage; ear pruri tus; tinni tus; oralmoniliasis; crying; dizziness; anderythema. Acute Otitis Externa: The followi ngtreatme nt-related adverseevents occurred in 0.4% or more of the patients with intact tympanic membranes.
In cidencefN=537) Earoruritus 1.5%
Ear debris
0.6% Superimposedearinfection 0.6% Earccnc estion 0.4% Earpain 0.4% Ervthema 0.4% Thefollowing treatment -related adverse events were eachreported in a single patient ear discomfort decreasedhearing; and eardisorder (tingling). HOW SUPPLIED CIPROOEX'(ciprofloxac in 0.3% anddexamethasone0.1%1Steril e OticSuspension is suppliedasfollows: 5 mL fill and 7.5 mL fill in a DROP-TAINER" system. The OROP-TAINER' system consists of a natural polyethylene bottleand natural plug, with a white pol ypropylene closure. Tamper evidence is provid ed with a shrink band around the closure and neck area of the package. NOC 0065-8533·01 , 5 mLfill; NOC 0065· 8533·02,7.5mLfill. Storage: Store at controlledroomtemperature, 15°Cto 30°C(59°Fto 86°F). Avoid freezing. Protectfromlight Clinical Studies: In a randomized, mul ticenter, controlled clinical trial, CIPRODEJ<O Otic dosed 2 times per day for 7 days demonstrated clinical cures in the per protocol analysis in 86% of AOMT patients compared to 79% for ofloxacin solution, 0.3%, dosed 2 times per day for 10 days. Among culture positive patients, clinical cures were 90% for CIPRODEJ<O Otic compared to 79% for ofJ oxacin solution, 0.3%. Microbiol ogi cal eradication rates for these patients in the same clinical trial were 91 % for CIPRODEX' Otic compared to 82% for olloxacin solution, 0.3%. In 2 randomized multicenter, controlled clinical trials, CI PRODEX ' Otic dosed 2 times per day for 7 days demonstrated clinical cures in 87% and 94% of per protocol evaluable AOE patients, respectively, compared to 84% and 89%, respectivel y, for otic suspension containing neomycin 0.35%, polymyxin B 10 ,000 IU/ mL, and hydrocortisone 1.0% (neo/poly/HC) . Among culture positive patients clinical cures were 86% and 92% for CIPROOEX ' Otic compared to 84% and89%, respectively, for neo/pol y/HC. Microbiological eradication rates for these patientsinthe sameclinical trials were86%and92%for CIPROD EJ<O Oticcomparedto85% and85%, respectivel y, for neo/poly/HC. 
DOSAGE AND ADMINISTRATION CIPRODEX ' OTIC SHOULD BESHAKEN WELL IMMEDIATELY BEFORE USE
SIN USOIDAL VERT ICAL AXIS ROTATION TEST
